UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at D. Boral Capital

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reissued by D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $25.00 target price on the stock. D. Boral Capital’s price objective indicates a potential upside of 132.13% from the stock’s current price.

UroGen Pharma Stock Up 2.2 %

URGN opened at $10.77 on Tuesday. The company has a market capitalization of $252.56 million, a PE ratio of -3.42 and a beta of 1.08. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma has a fifty-two week low of $9.78 and a fifty-two week high of $20.70. The business has a 50-day moving average of $10.79 and a 200-day moving average of $12.26.

Insider Buying and Selling at UroGen Pharma

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company’s stock.

Institutional Trading of UroGen Pharma

Large investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new position in UroGen Pharma in the 4th quarter worth $59,000. Lazard Asset Management LLC bought a new position in shares of UroGen Pharma in the fourth quarter worth about $67,000. Aquatic Capital Management LLC acquired a new position in shares of UroGen Pharma during the 4th quarter worth about $101,000. China Universal Asset Management Co. Ltd. boosted its stake in UroGen Pharma by 90.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after purchasing an additional 3,856 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after buying an additional 5,890 shares during the last quarter. 91.29% of the stock is owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.